TCR2 Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

TCR2 Therapeutics

22/03/2022 11:17

* TCR2 Therapeutics Inc  TCRR.OQ  reported a quarterly
adjusted
loss of 72 cents​​ per share for the quarter ended in December.
The mean expectation of nine analysts for the quarter was for a
loss of 75 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * TCR2 Therapeutics Inc's reported EPS for the quarter was a
loss
of 72 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * TCR2 Therapeutics Inc shares had fallen by 41.0% this
quarter.
    * The company reported a quarterly loss of $27.74 million.
    * Wall Street's median 12-month price target for TCR2
Therapeutics
Inc is $20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 22 at 11:17 a.m.  ​All
figures in US dollars unless otherwise stated